News
12-02-2011, 02:42 AM
Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin-(trastuzumab).
More... (http://www.news-medical.net/news/20111202/First-results-from-whole-genome-sequencing-clinical-trial-on-triple-negative-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20111202/First-results-from-whole-genome-sequencing-clinical-trial-on-triple-negative-breast-cancer.aspx)